Evidence map›Paper›PMID 38648198›Full record

ArticlePLoS biology2024

The impact of phage and phage resistance on microbial community dynamics.

Ellinor O Alseth, Rafael Custodio, Sarah A Sundius, Rachel A Kuske, Sam P Brown, Edze R Westra

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Phages and quorum sensing: findings to consider in phage therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  7. Fidelity in co-diversified symbiosis.Nature communications · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Exploring phage-host interactions inMicrobiology spectrum · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ellinor O AlsethEnvironment and Sustainability Institute, Biosciences, University of Exeter, Penryn, United Kingdom.ORCID 0000-0001-5665-6795
Rafael CustodioEnvironment and Sustainability Institute, Biosciences, University of Exeter, Penryn, United Kingdom.
Sarah A SundiusCenter for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Rachel A KuskeCenter for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Sam P BrownCenter for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Edze R WestraEnvironment and Sustainability Institute, Biosciences, University of Exeter, Penryn, United Kingdom.
Georgia Institute of Technology · USUniversity of Exeter · GB

Funding

Building re-usable phage and antibiotic treatments via exploitation of bacteria-phage co-evolutionary dynamicsR21AI156817 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI BROWN, SAMUEL PAUL · 2021 to 2022
$434k
NIAID NIH HHS R21 AI156817
6 · The paper itself

Abstract

Where there are bacteria, there will be bacteriophages. These viruses are known to be important players in shaping the wider microbial community in which they are embedded, with potential implications for human health. On the other hand, bacteria possess a range of distinct immune mechanisms that provide protection against bacteriophages, including the mutation or complete loss of the phage receptor, and CRISPR-Cas adaptive immunity. While our previous work showed how a microbial community may impact phage resistance evolution, little is known about the inverse, namely how interactions between phages and these different phage resistance mechanisms affect the wider microbial community in which they are embedded. Here, we conducted a 10-day, fully factorial evolution experiment to examine how phage impact the structure and dynamics of an artificial four-species bacterial community that includes either Pseudomonas aeruginosa wild-type or an isogenic mutant unable to evolve phage resistance through CRISPR-Cas. Additionally, we used mathematical modelling to explore the ecological interactions underlying full community behaviour, as well as to identify general principles governing the impacts of phage on community dynamics. Our results show that the microbial community structure is drastically altered by the addition of phage, with Acinetobacter baumannii becoming the dominant species and P. aeruginosa being driven nearly extinct, whereas P. aeruginosa outcompetes the other species in the absence of phage. Moreover, we find that a P. aeruginosa strain with the ability to evolve CRISPR-based resistance generally does better when in the presence of A. baumannii, but that this benefit is largely lost over time as phage is driven extinct. Finally, we show that pairwise data alone is insufficient when modelling our microbial community, both with and without phage, highlighting the importance of higher order interactions in governing multispecies dynamics in complex communities. Combined, our data clearly illustrate how phage targeting a dominant species allows for the competitive release of the strongest competitor while also contributing to community diversity maintenance and potentially preventing the reinvasion of the target species, and underline the importance of mapping community composition before therapeutically applying phage.

Indexed as

BacteriophagesCRISPR-Cas SystemsMicrobiotaPseudomonas aeruginosaAcinetobacter baumanniiBacteriaMutation

Identifiers

PMID38648198
PMCPMC11034675
OpenAlexW4394996083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.